Stan Abel, CEO of ProJenX,  the company leading the way in the development of targeted therapies to address significant unmet medical needs in degenerative brain diseases, with a special focus in amyotrophic lateral sclerosis (ALS), discusses the Phase 1 clinical study of Prosetin  in healthy volunteers and people with ALS (PRO-101) which is on track to initiate a Phase 2/3 study in 2023. 

Stan E. Abel  is the Chief Executive Officer of ProJenX. Abel joins the company after its recent launch by Medical Excellence Capital in collaboration with Project ALS, a leading nonprofit organization committed to ALS research, and with renowned researchers at Columbia University.Abel, who has more than 20 years of senior management and financial experience in the life sciences industry, has an extensive background in building and leading biopharmaceutical companies. Under his leadership, executive teams with emerging businesses have identified and in-licensed development-stage drug candidates, raised more than $100 million to fund operations, conducted large-scale clinical trials and implemented successful M&A strategies. Prior to joining ProJenX, Abel was CEO of SiteOne Therapeutics Inc., where he led a team developing new treatments for acute and chronic pain. Before this, he was CEO of Corthera Inc. through its sale to Novartis with a focus on a new treatment for heart failure. Earlier in his career, Abel was the CFO of Cerexa Inc. from its inception through its sale to Forest Laboratories. In addition, he was CFO of Peninsula Pharmaceuticals Inc. through its sale to Johnson & Johnson. Abel began his career in finance positions with Eli Lilly and Company and DowBrands Inc.Abel earned a B.S. in business from Indiana University and an M.B.A., with honors, from the University of Chicago Booth School of Business. He is chairman of SiteOne Therapeutics and serves as an advisor to early-stage life science companies.

Liked it? Take a second to support healthprofessionalradio on Patreon!